CompletedPhase 1NCT02294656

Acute Pseudophakic Cystoid Macular Edema Treatment Trial: Intravitreal Ranibizumab Versus Triamcinolone Acetonide

Studying Cystoid macular dystrophy

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Soll Eye
Principal Investigator
DAVID RHO, MD
Soll Eye
Intervention
Ranibizumab,(drug)
Enrollment
4 enrolled
Eligibility
18 years · All sexes
Timeline
2014 – 2018

Study locations (1)

Collaborators

Genentech, Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02294656 on ClinicalTrials.gov

Other trials for Cystoid macular dystrophy

Additional recruiting or active studies for the same condition.

See all trials for Cystoid macular dystrophy →

← Back to all trials